Clinical trial
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
NCT02246764 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
- Lead sponsor
- Aerie Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2014
- Completion date
- December 31, 2016
- Enrollment
- 93 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.